Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Fuel Tech Q4 2025 Earnings Call - Data center pipeline of $75-100M offers upside, but timing and visibility are limited
Fuel Tech closed 2025 with a tidy cash cushion and a clear story line, revenue up in Q4 driven by both APC and FUEL CHEM, while full-year growth was modest. The quarter showed healthy margins and a sh...
- Q4 2025 consolidated revenue rose 37% year-over-year to $7.2 million, with APC and FUEL CHEM each contributing a 37% increase.
- Full-year 2025 revenue increased 6% to $26.7 million, driven primarily by a 28% rise in FUEL CHEM revenue to $17.8 million, the highest FUEL CHEM level since 2018.
- Consolidated growth margin improved to 45% in Q4 from 42% a year earlier, and full-year growth margin rose to 46% from 42% in 2024.
- +13 more takeaways
The Eastern Company Q4 FY2025 Earnings Call - Built the Foundation: cost cuts, tariff mitigation, refinancing, and early demand stabilization
Eastern finished a bruising 2025 by reshaping the business rather than pretending volumes would rebound. Revenue fell to $249 million, down 9% year-over-year, and adjusted EBITDA slipped to $19.4 mill...
- Full-year 2025 revenue $249.0M, down 9% versus 2024.
- Adjusted EBITDA $19.4M for 2025, a 7.8% margin versus 9.6% in 2024.
- Q4 2025 net sales $57.5M, down 13.7% year-over-year from $66.7M, but up 4% sequentially from Q3.
- +16 more takeaways
Advanced Flower Capital Q4 2025 Earnings Call - BDC Conversion Expands Pipeline While Legacy Loans Still Drag
Advanced Flower Capital completed its conversion from a REIT to a BDC on January 1, 2026, unlocking a much larger investable universe and swelling its active pipeline to $1.4 billion from $400 million...
- AFC completed its conversion from a REIT to a BDC effective January 1, 2026, expanding the investable universe beyond real estate-backed loans.
- Management received $117 million of paydowns from performing and underperforming credits from the start of 2025 through the date of the call.
- For fiscal 2025, AFC originated $53 million of new commitments, and subsequently closed $89.7 million of new commitments in the lower middle market.
- +15 more takeaways
Orion Group Holdings Full Year 2025 Earnings Call - M&A and New Assets Boost Capacity as Backlog Lags on Timing
Orion closed 2025 with clear operational progress: revenue rose to $852 million, Adjusted EBITDA to $45 million and the marine business more than doubled its Adjusted EBITDA to $56 million. Management...
- FY2025 results: revenue $852 million, operating income $15 million, Adjusted EBITDA $45 million, Adjusted EPS $0.25 per share.
- Cash flow and liquidity: operating cash flow $28 million, free cash flow $14 million; year-end net debt about $6 million (prior to Feb draw).
- Marine segment strength: revenue $545 million (up 4.5% year over year), Adjusted EBITDA $56 million, reported Marine Adjusted EBITDA margin 10%, contribution margin 15%.
- +11 more takeaways
Orion Group Holdings Full Year 2025 Earnings Call - $23B Pipeline, McAmis Buy and Derrick Barge Set Stage for 2026 Growth
Orion closed 2025 with clear progress on operations and balance sheet repair. Revenue rose to $852 million, Adjusted EBITDA was $45 million, Adjusted EPS $0.25, operating cash flow $28 million and fre...
- 2025 results improved: revenue $852 million, Adjusted EBITDA $45 million, Adjusted EPS $0.25, operating cash flow $28 million, free cash flow $14 million.
- 2026 guidance: revenue $900M-$950M, Adjusted EBITDA $54M-$58M, Adjusted EPS $0.36-$0.42, capex $25M-$35M.
- Booked $763 million of new contracts and change orders in 2025, a 0.9x book-to-bill, with management framing the shortfall as timing rather than demand loss.
- +11 more takeaways
Nexxen Q4 2025 Earnings Call - V Partnership and Programmatic Smart TV Home Screen Power 2026 Momentum
Nexxen closed 2025 with mixed results and a clear pivot into programmatic CTV, data products, and enterprise DSP adoption. Q4 contribution ex-TAC was $97.8 million, down 7% year‑over‑year, and program...
- Q4 contribution ex-TAC was $97.8 million, down 7% year‑over‑year, and programmatic revenue was $94.3 million, down 4% year‑over‑year but up 2% excluding political spend.
- Management reports record January and February 2026 months, saying Q1 programmatic contribution ex-TAC is pacing ahead of initial expectations.
- Nexxen launched what it calls the industry’s first programmatic Smart TV on‑screen solution, converting OEM home screens into programmatic inventory integrated with V (formerly VIDAA).
- +12 more takeaways
Mayville Engineering Company Q4 2025 Earnings Call - Data center ramp drives short-term margin pain, sets stage for >20% revenue mix in 2026
MEC called Q4 a transitional quarter. Management reallocated capacity to support an accelerating data center and critical power ramp after the Accu-Fab acquisition, which drove top-line growth but pro...
- Q4 sales rose 10.7% year over year to $134.3 million, but organic sales excluding Accu-Fab declined 5.3%.
- Margin hit was explicit and quantified, manufacturing margin fell to 6.6% from 8.9% last year, and Adjusted EBITDA margin declined to 4.7% from 7.6%.
- Management attributes margin pressure to transitory items, specifically $1.2 million of data center launch costs and $1.7 million of early-stage commercial vehicle project inefficiencies.
- +12 more takeaways
Dycom Industries Fourth Quarter 2026 Earnings Call - Record revenue and Power Solutions deal pushes Dycom into data center and fiber markets
Dycom closed fiscal 2026 with record revenue and a stretched backlog, while using a large acquisition to pivot into the data center ecosystem. The quarter and year delivered top-line beats, margin exp...
- Q4 FY2026 revenue hit a record $1.458 billion, up 34.4% year-over-year, with organic Q4 growth of 16.6% after adjusting for Power Solutions and the extra fiscal week.
- Full-year FY2026 revenue set a record at $5.55 billion, up 17.9% year-over-year, with organic revenue up 6.5% for the year.
- Adjusted EBITDA for Q4 was $162.4 million, with an adjusted EBITDA margin of 11.1%, up about 41 basis points year-over-year. Full-year adjusted EBITDA was $737.7 million, with a margin of 13.3%, up 105 basis points versus FY2025.
- +16 more takeaways
Ocugen Q4 2025 Earnings Call - OCU400 rolling BLA to start in Q3 2026 after completing liMeliGhT enrollment; top-line Phase III data due Q1 2027
Ocugen closed 2025 with enrollment complete in its broad, gene-agnostic OCU400 Phase III liMeliGhT study and positive long-term Phase I/II durability data, and management plans to begin a rolling BLA ...
- OCU400 (retinitis pigmentosa) enrollment complete in the Phase III liMeliGhT trial: 140 patients randomized 2:1 across gene-specific and gene-agnostic arms; primary endpoint is 12-month change in Luminance Dependent Navigation Assessment (LDNA).
- Management expects to start a rolling BLA submission for OCU400 in Q3 2026, with top-line Phase III data anticipated in Q1 2027 and potential approval in 2027 if data support filing.
- Long-term Phase I/II OCU400 data show sustained ~two-line LLVA gain at three years, with no new treatment-related serious adverse events reported, supporting durability and safety claims.
- +12 more takeaways
Cellectar Biosciences Fourth Quarter and Full Year 2025 Earnings Call - Iopofosine advances toward EU CMA and US Accelerated Approval after 12-month data
Cellectar finished 2025 with regulatory clarity and a narrowed path to market for its lead radiotherapeutic, iopofosine I 131. Management says they now have 12 months of follow-up on all CLOVER-WaM pa...
- Iopofosine I 131 is the lead asset, and Cellectar plans to submit a Conditional Marketing Authorisation application to the EMA in Q3 2026, targeting potential European commercialization as early as 2027.
- Company reports 12 months of follow-up on all CLOVER-WaM patients, and management says the mature data show improved response rates, durability, progression-free survival, and duration of response versus the December 2024 cut.
- Cellectar intends to pursue US Accelerated Approval under its Breakthrough Therapy designation, with an NDA submission shortly after initiating the confirmatory Phase III in a post-BTKi, second-line population.
- +17 more takeaways